As a member of the TORCH complex, cytomegalovirus can cause congenital infection. Because of this, there has been considerable effort made towards the development of a vaccine, with particular emphasis on protection for pregnant women. (Cytomegalovirus also has a major impact upon individuals with acquired or induced immune deficiency, but because vaccination of the immunocompromised introduces additional challenges, members of this population are less likely to be candidates for such a vaccine.)
recDB has been suggested as a target.
A phase 2 study of a CMV-vaccine published in 2009 indicated an efficacy of 50%, - thus the protection provided was limited and a number of subjects contracted CMV infection despite the vaccination. In one case also congenital CMV was encountered.